Skip to main content

Table 2 Patients' features

From: Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)

  c.35 G>A KRASmutant Other KRASmutant KRASwild-type
  Total Number (%) Total Number (%) Total Number (%)
Number of patients 15 (25) 13 (22) 31 (53)
Sex    
   male/female 11/4 5/8 21/10
Age, years    
   median 67 63 64
   range 51 to 73 48 to 71 42 to 73
   ≥65 years 8 (53) 5 (38) 13 (42)
WHO Performance Status    
   0 13 (87) 13 (100) 28 (90)
   1-2 2 (13) - 3 (10)
Metastatic disease    
   metachronous 5 (33) 2 (15) 10 (32)
   synchronous 10 (67) 11 (85) 21 (68)
Primary tumor    
   colon 10 (67) 10 (77) 14 (45)
   rectum 5 (33) 3 (23) 17 (55)
Sites of metastases    
   liver 12 (80) 8 (61.5) 19 (61)
   lung 3 (20) 2 (15) 7 (23)
   lymph nodes 4 (27) 4 (31) 10 (32)
   local 2 (13) 1 (8) 6 (19)
   other 4 (27) 2 (15) 2 (6)
Number of involved sites    
   1 8 (53) 9 (69) 17 (55)
   ≥2 7 (47) 4 (31) 14 (45)
Single metastatic sites    
   liver-limited 6 (40) 7 (54) 12 (39)
   other than liver 2 (13) 2 (15) 7 (22)
lung 1 (6.5) 1 (8) 2 (6)
lymph nodes - 1 (8) 2 (6)
Local 1 (6.5) - 3 (10)
multiple metastatic site 7 (47) 4 (31) 12 (39)
Liver metastases    
   single 2 (13) 1 (8) 8 (26)
   multiple 10 (67) 7 (54) 11 (35)
Previous adjuvant chemotherapy: 1 (6.5) 1 (8) 6 (19)
   FA/5-FU bolus - - 3 (10)
   Capecitabine - - -
   FOLFOX4 1 (6.5) 1 (8) 2 (6)
   XelOx - - 1 (3)
Previous radiotherapy: 1 (6.5) - 4 (13)
   RT alone - - -
   RT+CT (5-FU c.i.) - - 2 (6)
   RT+CT (XELOX) 1 (6.5) - 2 (6)
  1. c.i., continuous infusion; WHO, World Health Organization.